| Identification | Back Directory | [Name]
insulin glargine | [CAS]
160337-95-1 | [Synonyms]
Lantus
Solostar
Unii-2zm8cx04rz
insulin glargine
Insulin Glargine RS
Insulin glargine CRS
Insulin Glargine EP/USP
insulin glargine USP/EP/BP
Insulin Glargine, recombinant
Solostar [insulin delivery pen]
A21-Gly-B31-Arg-B32-Arg-insulin
Insulin, glycyl(A21)-arginyl(B31,B32)-
Insulin glargine for peak identification CRS
Insulin glargine for peak identification (Y0001544)
Insulin (human),21A-glycine-30Ba-Larginine- 30Bb-L-arginine-
Insulin glargine United States Pharmacopeia (USP) Reference Standard | [Molecular Formula]
C267H404N72O78S6 | [MDL Number]
MFCD09260251 | [MOL File]
160337-95-1.mol | [Molecular Weight]
6062.89 |
| Chemical Properties | Back Directory | [storage temp. ]
-20°C, Inert atmosphere | [solubility ]
Aqueous Acid (Very Slightly) | [form ]
neat | [color ]
White to Off-White | [Sequence]
A-chain: Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Gly; B-chain: Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr-Arg-Arg (Disulfide bridge: CysA6-CysA11, CysA7-CysB7, CysA20-CysB19) | [CAS DataBase Reference]
160337-95-1 |
| Hazard Information | Back Directory | [Uses]
long-acting basal insulin analogue, helping control the blood sugar level of those with type 1 and type 2 diabetes mellitus. It is an analogue of human insulin made by replacing the asparagine residue at position A21 of the A-chain with glycine and adding | [Brand name]
Lantus (Hoechst Marion Roussel). | [Biological Activity]
Insulin glargine is an approved long-acting insulin analog used for management of Diabetes Type 1 and Type 2. Insulin glargine is a human insulin analog where A-chain asparagine 21 was replaced by glycine and B-chain carboxy terminal was extended by two arginine residues. | [in vivo]
Insulin glargine (2-12.5 IU/kg; subcutaneous injection; 3-12 months) does not present a carcinogenic risk in rodents[2].
Insulin glargine (450 mg/kg; subcutaneous injection; 6 months) has an improving effect in a mouse model of diabetes[3]. | Animal Model: | Seven-week-old male db/db mice[3] | | Dosage: | 450 mg/kg | | Administration: | Subcutaneous injection (s.c.); 6 months | | Result: | Significantly improved glucose tolerance.
Upregulated pancreatic β-cell functional genes, such as INS1, Pdx1, Pax4 and Pax6.
|
|
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|